ŘIHÁČKOVÁ, Eva, Michal ŘIHÁČEK, Mária VYSKOČILOVÁ, Dalibor VALÍK and Lubomír ELBL. Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma-a review and prospects for the future. Frontiers in Cardiovascular Medicine. Lausanne: Frontiers, 2023, vol. 10, August 2023, p. 1-16. ISSN 2297-055X. Available from: https://dx.doi.org/10.3389/fcvm.2023.1243531. |
Other formats:
BibTeX
LaTeX
RIS
@article{2307377, author = {Řiháčková, Eva and Řiháček, Michal and Vyskočilová, Mária and Valík, Dalibor and Elbl, Lubomír}, article_location = {Lausanne}, article_number = {August 2023}, doi = {http://dx.doi.org/10.3389/fcvm.2023.1243531}, keywords = {lymphoma; cardiotoxicity; chemotherapy; modern treatment; prevention; cardiac adverse events}, language = {eng}, issn = {2297-055X}, journal = {Frontiers in Cardiovascular Medicine}, title = {Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma-a review and prospects for the future}, url = {https://www.frontiersin.org/articles/10.3389/fcvm.2023.1243531/full}, volume = {10}, year = {2023} }
TY - JOUR ID - 2307377 AU - Řiháčková, Eva - Řiháček, Michal - Vyskočilová, Mária - Valík, Dalibor - Elbl, Lubomír PY - 2023 TI - Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma-a review and prospects for the future JF - Frontiers in Cardiovascular Medicine VL - 10 IS - August 2023 SP - 1-16 EP - 1-16 PB - Frontiers SN - 2297055X KW - lymphoma KW - cardiotoxicity KW - chemotherapy KW - modern treatment KW - prevention KW - cardiac adverse events UR - https://www.frontiersin.org/articles/10.3389/fcvm.2023.1243531/full N2 - Treatment of malignant lymphoma has for years been represented by many cardiotoxic agents especially anthracyclines, cyclophosphamide, and thoracic irradiation. Although they are in clinical practice for decades, the precise mechanism of cardiotoxicity and effective prevention is still part of the research. At this article we discuss most routinely used anti-cancer drugs in chemotherapeutic regiments for malignant lymphoma with the focus on novel insight on molecular mechanisms of cardiotoxicity. Understanding toxicity at molecular levels may unveil possible targets of cardioprotective supportive therapy or optimization of current therapeutic protocols. Additionally, we review novel specific targeted therapy and its challenges in cardio-oncology. ER -
ŘIHÁČKOVÁ, Eva, Michal ŘIHÁČEK, Mária VYSKOČILOVÁ, Dalibor VALÍK and Lubomír ELBL. Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma-a review and prospects for the future. \textit{Frontiers in Cardiovascular Medicine}. Lausanne: Frontiers, 2023, vol.~10, August 2023, p.~1-16. ISSN~2297-055X. Available from: https://dx.doi.org/10.3389/fcvm.2023.1243531.
|